Key Takeaway: Cognition Therapeutics is conducting Phase 2 trials for Zervimesine, targeting conditions such as Dry AMD, Alzheimer's, and Dementia with Lewy Bodies. The article indicates that these trials show promise, but does not provide specific results or details on the outcomes. Further information on the trials or their implications is not included.
Price reaction · baseline $0.3138 (2025-05-22T13:59:00.000Z) · hit during market hours · 1 other CGTX headline(s) in the window, move may be shared
day 0 close · peak
+0.4%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
8.3%
average across 6 past catalysts
Cash runway
~33 mo
Minimal dilution risk
Lead asset
Oxytocin
Phase 2 · Oxidative Stress
Full Press Release Details
You are now leaving the Cognition Therapeutics website
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.